iconstar paper   Hepatitis C Articles (HCV)  
Back grey arrow rt.gif
HCV Drug Interactions & Switching Patient's ART Regimen in order to take HCV Therapy - Clin Pharm Workshop
  Readying HIV/HCV Coinfected Patients for HCV Treatment: Occurrence and Management of Antiviral Interactions....[can patients switch their HIV regimen?] - (06/01/15).....potential moderate or severe interactions with at least 1 of the 4 HCV regimens were identified in 70.4% (88/125) patients......20% - 7 of the 35 patients - would NOT be eligible to change their HIV regimen due to resistance...
16th International Workshop on Clinical Pharmacology of HIV and Hepatitis Therapy
May 26-28, 2015 Washington, DC
BMS Daclatasvir
Population Viral Kinetic Modeling: SVR Prediction in HCV GT-3 Cirrhotic Patients With 24 Weeks of Daclatasvir + Sofosbuvir Administration - (05/29/15)
Model Predicts Higher SVR With 24- vs 12-Week Daclatasvir/Sofosbuvir for HCV-3 Cirrhotics - written by Mark Mascolini - (05/29/15)
Assessment of Drug-Drug Interactions Between Daclatasvir and Darunavir/Ritonavir or Lopinavir/Ritonavir - (06/03/15)
Therapeutic drug monitoring of daclatasvir in HIV/HCV co-infected patients receiving darunavir/ritonavir 800/100mg once-daily - (06/01/15)
Evaluation of Drug Interactions between Dolutegravir and Daclatasvir in Healthy Subjects - (05/29/15)
Standard Daclatasvir Dose OK With Darunavir/RTV or Lopinavir/RTV - written by Mark Mascolini - (06/01/15)
Triple-DAA Combo Cuts SSRI Levels by One Third, But No Dose Adjustment Needed - written by Mark Mascolini - (06/01/15)
Gilead Harvoni - Sofosbuvir
Drug Interactions Between Anti-HCV Antivirals Ledipasvir/Sofosbuvir and Integrase Strand Transfer Inhibitor-Based Regimens......"LDV/SOF may be coadministered with E/C/F/TAF without monitoring" - (06/03/15)
Drug Interactions Between the Anti-HCV Regimen Ledipasvir/Sofosbuvir and Antiretrovirals - (06/03/15)
Evaluation of PK/PD Relationships Between Ribavirin and Sustained Virologic Response in HCV-Genotype 3 Infected Subjects in the Sofosbuvir Phase 3 Program - (05/29/15)
Abbvie 3D/2D
Ombitasvir/Paritaprevir/Ritonavir + Dasabuvir: Drug Interactions with Antiretroviral Agents - (06/01/15)
Drug-Drug Interactions of Ombitasvir/Paritaprevir/r plus Dasabuvir with Dolutegravir or Abacavir plus Lamivudine - (06/08/15)
Drug-Drug Interactions of Commonly Used Medications with Direct Acting Antiviral HCV Combination Therapy of Paritaprevir/r, Ombitasvir and Dasabuvir - (06/08/15)
Pharmacokinetics of Dasabuvir when Administered with Ombitasvir, Paritaprevir and Ritonavir in Healthy Volunteers - (06/08/15)
Effect of Comedications on Paritaprevir, Ritonavir, Ombitasvir, Dasabuvir and Ribavirin Pharmacokinetics - (06/08/15)
Drug Interactions with Direct Acting Antiviral Combination of Paritaprevir/Ritonavir + Ombitasvir - (06/08/15)
Possible Dose Adjustments With Four Drugs and Abbvie 3D HCV Regimen - written by Mark Mascolini - (06/01/15)
Merck Grazoprevir/Elbasvir
Drug-Drug Interactions with Grazoprevir/Elbasvir: Practical Considerations for the Care of HIV/HCV Co-Infected Patients - (06/03/15)
No Pharmacokinetic Interaction Between HCV Inhibitors Grazoprevir/Elbasvir with Rilpivirine - (06/08/15)
Coadministration of HCV Protease Inhibitor Grazoprevir With HCV NS5A Inhibitor Elbasvir Has No Effect On Pravastatin But Increases Rosuvastatin Exposure In Healthy Subjects - (06/08/15)

  iconpaperstack View Older Articles   Back to Top   www.natap.org